Research & Development
Metagenomics study finds antibiotic resistance genes are widespread among bacteria
Bacteria everywhere carry previously unknown genes that make them resistant to antibiotics, potentially aggravating the problem of untreatable bacterial infections.
June 6, 2023
FDA clears Becton Dickinson MRSA imaging software
The software leverages AI to automate the traditionally labor- and time-intensive task of inspecting Petri dishes to determine whether there is bacterial growth.
May 16, 2023
AACC releases guidance on procalcitonin testing for patients with bacterial infections
Procalcitonin tests have been used for many years in Europe, but only became available in the U.S. in 2017, when the FDA approved them as tools to help guide antibiotic treatment, among other uses.
May 5, 2023
Antibiotic susceptibility test in study reveals current antibiotics may cure superbugs
The test revealed that some of the commercial, FDA-approved antibiotics can treat drug-resistant superbug infections.
May 1, 2023
Genetic variations in study increased H. pylori-related stomach cancer risk
According too the study, people carrying genetic risk factors for stomach cancer have an increased risk if they’ve also been infected by the bacterium Helicobacter pylori.
March 30, 2023
Laser light method identifies bacteria in fluids
An innovative way of shining a laser on a minute drop of blood, mucus, or wastewater enables the reflected light to identify the bacteria within.
March 3, 2023
Tulsa ER & Hospital adopts MeMed host-response test to quickly distinguish between bacterial and viral infections
Israel-based MeMed said it leverages machine learning to translate the complex signaling of the immune system into diagnostic insights.
December 22, 2022
Guidance for antibiotics, diagnostics use in an epidemic
In a statement published Wednesday in Infection Control & Hospital Epidemiology, SHEA provided strategies for hospitals and healthcare personnel to improve antibiotic prescribing when they encounter new infectious disease outbreaks.
September 14, 2022
DiaSorin nabs FDA clearance for infectious disease blood test
The fully automated test utilizes host response-based data to enable physicians to differentiate accurately between bacterial and viral infections, supporting faster and better-informed treatment and patient management decisions, DiaSorin said.
July 21, 2022
Inflammatix lands $12.1M in new BARDA deal
The company's third tranche of funding from BARDA is part of a contract worth up to $72 million if all options are exercised. Inflammatix said it would use the funds for ongoing development and clinical studies of its ViraBac EZ acute infection test, which determines whether a suspected infection is bacterial or viral based on gene expression patterns in the immune system.
November 18, 2021
Lumos touts cost savings for point-of-care infection test
FebriDx is a finger-stick blood test that distinguishes bacterial from viral acute respiratory infections. The study, published September 30 in the Journal of Health Economics and Outcomes Research, found that FebriDx had a sensitivity of 95% to detect bacterial infections and a negative predictive value of 99% to rule out these infections.
October 6, 2021
Inflammatix secures $102M in financing
Inflammatix's diagnostics use machine-learning algorithms to track a patient's immune response to infections across multiple messenger RNA (mRNA) biomarkers, it said. The tests identify whether an infection is viral or bacterial and help clinicians gauge the risk of severe disease, including COVID-19, producing results in less than 30 minutes, according to the firm.
March 15, 2021
Page 1 of 3